WEST Search History

| Hide Items | Restore | Clear | Cancel |

DATE: Tuesday, October 18, 2005

Hide?	**Set Name**	**Query**	**Hit Count**
		DB=USPT; PLUR=NO; OP=OR	
☐	L4	L3 and display and variegat$$$$	28
☐	L3	librar$$$$ same cdr	404
☐	L2	variegated same cdr	4
☐	L1	6906176.pn.	1

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 13:39:05 ON 18 OCT 2005)

FILE 'REGISTRY' ENTERED AT 13:39:23 ON 18 OCT 2005
L1   1042 S RASQ.V...LA/SQSP
L2   1623 S I..SGG.T.YADSVKG/SQSP
L3   0 S L2&L1/SQSFP
L4   3 S L2 AND L1

FILE 'CAPLUS' ENTERED AT 13:41:52 ON 18 OCT 2005
L5   2 S L4 AND LIBRAR?
L6   3 S L4

FILE 'REGISTRY' ENTERED AT 13:44:27 ON 18 OCT 2005
L7   464 S AYAMA/SQSP
L8   0 S L7 AND L1
L9   0 S L7 AND L2
L10   1665 S AASSAA/SQSP
L11   0 S L10 AND L7
L12   0 S QQYAAAPAT/SQSP
L13   0 S TGTSSDVGTYDYVS/SQSP

FILE 'CAPLUS, MEDLINE, SCISEARCH, BIOSIS' ENTERED AT 13:50:07 ON 18 OCT
2005
L14   0 S VARIEGATED LIBRAR?
L15   1 S VARIEGATED AND CDR AND LIBRAR?
             E LADNER ROBERT CHARLES/AU
L16   122 S E1-E3
L17   0 S L15 AND L16
L18   1 S L16 AND CDR AND LIBRAR?
L19   1 S L16 AND VECTOR# AND VARIEGATE?

L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN   1995:892928 CAPLUS
DN   123:308167
ED   Entered STN: 03 Nov 1995
TI   Process for generating antibodies specific for immunorecessive epitopes by
     generation of display **library** of variable regions from
     immunotolerance-derived antibodies
IN   Barsomian, Gary; Copeland, Diane P.; Hillhouse, Dana; Johnson, Tracy
PA   Genzyme Corp., USA
SO   PCT Int. Appl., 109 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
IC   ICM C07K016-00
     ICS C12N015-13
CC   3-1 (Biochemical Genetics)
     Section cross-reference(s): 15
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9515982	A2	19950615	WO 1994-US14106	19941208
WO 9515982	A3	19951228		

    W: AU, CA, JP
    RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2175482	AA	19950615	CA 1994-2175482	19941208
AU 9514321	A1	19950627	AU 1995-14321	19941208
AU 696293	B2	19980903		
EP 733070	A1	19960925	EP 1995-905871	19941208

    R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09506262	T2	19970624	JP 1994-516337	19941208
PRAI US 1993-164022	A	19931208		
US 1994-350400	A	19941206		
US 1994-164022	A	19941206		
WO 1994-US14106	W	19941208		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9515982	ICM	C07K016-00
	ICS	C12N015-13
WO 9515982	ECLA	C07K016/00; C12N015/62

AB   The present invention relates to a method for generating an antibody which
     is specific for an immunorecessive epitope, and nucleic acid encoding the
     antibody. The subject method generally comprises the steps of generating
     a **variegated** display **library** of antibody variable
     regions, and selecting from the **library** those antibody variable
     regions which have a desired binding specificity for the immunorecessive
     epitope. The antibody variable regions used to generate the display
     library are cloned from an immunotolerance-derived antibody
     repertoire. Thus, a specific antibody to an immunorecessive epitope (such
     as metastatic tumor cell or fetal nucleated red blood cell markers or
     tumor suppressor protein p53 mutants) can be generated by affinity purification
     of an antibody phage **library** derived from an
     immunotolerance-derived antibody repertoire. Using the described
     technique, fetal blood cell-specific Fab' fragments with Ka of 6-8 +
     1010 M-1 were prepared These antibodies were ≥40-fold more specific
     than prior art antibodies produced by hybridoma or immunotolerance
     techniques. Addnl., the antibody display phages were enriched 5000- to
     3.6 + 106-fold in a single round of selection by panning on live
     cells.
ST   antibody immunorecessive epitope specific phage display; immunotolerance
     technique immunorecessive epitope specific antibody
IT   Erythrocyte
         (antigenic marker for fetal; process for generating antibodies specific
         for immunorecessive epitopes by generation of display **library**
         of variable regions from immunotolerance-derived antibodies)
IT   Nerve
         (antigenic marker for precursor pf; process for generating antibodies

specific for immunorecessive epitopes by generation of display
library of variable regions from immunotolerance-derived
antibodies)
IT   Hematopoietic precursor cell
Neoplasm
(antigenic marker for; process for generating antibodies specific for
immunorecessive epitopes by generation of display library of
variable regions from immunotolerance-derived antibodies)
IT   Antigens
RL: MSC (Miscellaneous)
(immunorecessive epitope-containing; process for generating antibodies
specific for immunorecessive epitopes by generation of display
library of variable regions from immunotolerance-derived
antibodies)
IT   Escherichia coli
Virus, bacterial
(process for generating antibodies specific for immunorecessive
epitopes by generation of display library of variable regions
from immunotolerance-derived antibodies)
IT   Antibodies
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP
(Preparation)
(process for generating antibodies specific for immunorecessive
epitopes by generation of display library of variable regions
from immunotolerance-derived antibodies)
IT   Lipoproteins
RL: ANT (Analyte); ANST (Analytical study)
(apo-, E4, process for generating antibodies specific for
immunorecessive epitopes by generation of display library of
variable regions from immunotolerance-derived antibodies)
IT   Intestine, neoplasm
(colon, antigenic marker for; process for generating antibodies
specific for immunorecessive epitopes by generation of display
library of variable regions from immunotolerance-derived
antibodies)
IT   Embryo
(fetus, antigenic marker for cells of; process for generating
antibodies specific for immunorecessive epitopes by generation of
display library of variable regions from immunotolerance-
derived antibodies)
IT   G proteins (guanine nucleotide-binding proteins)
RL: ANT (Analyte); ANST (Analytical study)
(gene c-ras, variants; process for generating antibodies specific for
immunorecessive epitopes by generation of display library of
variable regions from immunotolerance-derived antibodies)
IT   Neoplasm
(metastatic, antigenic marker for; process for generating antibodies
specific for immunorecessive epitopes by generation of display
library of variable regions from immunotolerance-derived
antibodies)
IT   Cell
(stem, antigenic marker for; process for generating antibodies specific
for immunorecessive epitopes by generation of display library
of variable regions from immunotolerance-derived antibodies)
IT   Phosphoproteins
RL: ANT (Analyte); ANST (Analytical study)
(tumor suppressor, p53, variants; process for generating antibodies
specific for immunorecessive epitopes by generation of display
library of variable regions from immunotolerance-derived
antibodies)
IT   169182-78-9   169182-79-0   169182-80-3   169182-81-4   169182-82-5
169182-83-6
RL: PRP (Properties)
(CDR-containing region of anti-onco/fetal antigen antibody;
process for generating antibodies specific for immunorecessive epitopes
by generation of display library of variable regions from
immunotolerance-derived antibodies)
IT   169800-18-4   169800-19-5   169800-20-8   169800-21-9   169800-22-0

```
   169800-24-2    169800-26-4    169800-28-6    169800-30-0    169800-32-2
   169800-34-4
   RL: PRP (Properties)
       (amino acid sequence; process for generating antibodies specific for
       immunorecessive epitopes by generation of display library of
       variable regions from immunotolerance-derived antibodies)
IT 169681-92-9    169681-93-0    169681-94-1    169681-95-2    169681-96-3
   169681-97-4    169681-98-5    169681-99-6
   RL: PRP (Properties)
       (heavy chain CDR3 of anti-onco/fetal antigen antibody; process for
       generating antibodies specific for immunorecessive epitopes by
       generation of display library of variable regions from
       immunotolerance-derived antibodies)
IT 169682-00-2    169682-01-3    169682-02-4    169682-03-5    169682-04-6
   169682-05-7    169682-06-8    169682-07-9    169682-08-0    169682-09-1
   169682-10-4
   RL: PRP (Properties)
       (light chain CDR3 of anti-onco/fetal antigen antibody; process for
       generating antibodies specific for immunorecessive epitopes by
       generation of display library of variable regions from
       immunotolerance-derived antibodies)
IT 169800-23-1    169800-25-3    169800-27-5    169800-29-7    169800-31-1
   169800-33-3
   RL: PRP (Properties)
       (nucleotide sequence; process for generating antibodies specific for
       immunorecessive epitopes by generation of display library of
       variable regions from immunotolerance-derived antibodies)
```